Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 138

Results For "Director"

2831 News Found

Prevest Denpro launches range of innovative oral hygiene products ‘Oradox’
News | November 23, 2023

Prevest Denpro launches range of innovative oral hygiene products ‘Oradox’

The Oradox brand introduced a range of revolutionary products designed to elevate the standard of oral care


Azelis inks distribution agreement with Beneo in India and Bangladesh
Supply Chain | November 22, 2023

Azelis inks distribution agreement with Beneo in India and Bangladesh

Azelis will be the exclusive distributor for inulin, oligofructose, scFOS, texturized wheat proteins, faba beans, Beta-glucans, meatless solution


LTTS, NVIDIA to unveil Gen AI and software defined architecture for medical devices
Digitisation | November 21, 2023

LTTS, NVIDIA to unveil Gen AI and software defined architecture for medical devices

This innovative solution comes as an answer to the industry-wide challenges of availability, cost, and dependencies linked to custom and proprietary hardware components


AskBio announces first patient randomized in Phase 1 Trial of AB-1005
News | November 20, 2023

AskBio announces first patient randomized in Phase 1 Trial of AB-1005

Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels


FDA approves Merck’s Keytruda plus chemotherapy as first line treatment for locally advanced Metastatic HER2-Negative Gastric
Drug Approval | November 17, 2023

FDA approves Merck’s Keytruda plus chemotherapy as first line treatment for locally advanced Metastatic HER2-Negative Gastric

Approval based on results from the Phase 3 KEYNOTE-859 trial, which demonstrated significant improvement in overall survival in these patients versus chemotherapy alone


Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting
Drug Approval | November 17, 2023

Pfizer and Astellas' XTANDI approved by USFDA in earlier prostate cancer treatment setting

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy in nonmetastatic castration-sensitive prostate cancer


JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr
News | November 15, 2023

JB Pharma Q2 FY24 PAT up 36% to Rs. 151 Cr

Reports revenue growth of 9% to INR 882 crores in Q2 FY24


IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr
News | November 15, 2023

IOL Chemicals and Pharmaceuticals Q2 PAT jumps 141% to Rs. 37.8 Cr

EBITDA for Q2 FY24 at Rs. 71.2 crore as compared to Rs. 79.9 crore QoQ


Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr
News | November 13, 2023

Granules India Q2 FY24 PAT drops 30% at Rs. 102 Cr

Sales in the US region grew well, partially offset by the decline in the LATAM and European regions


Vaishali Pharma posts Q2 FY24 PAT at Rs. 1.70 Cr
News | November 13, 2023

Vaishali Pharma posts Q2 FY24 PAT at Rs. 1.70 Cr

he company posted total income during Q2 FY24 at Rs. 12.86 crore